Unity Biotechnology, Inc. (0YC0.L)
USD 0.87
(-4.92%)
USD 0.87
(-4.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 7.18 Million USD | -79.24% |
| 2022 | 34.62 Million USD | 85.61% |
| 2021 | 18.65 Million USD | -54.69% |
| 2020 | 41.16 Million USD | 210.0% |
| 2019 | -37.42 Million USD | -145.03% |
| 2018 | -15.27 Million USD | -115.26% |
| 2017 | -7.09 Million USD | 92.05% |
| 2016 | -89.28 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 15.17 Million USD | 111.16% |
| 2024 Q3 | 11.8 Million USD | -16.16% |
| 2024 Q2 | 14.07 Million USD | -7.25% |
| 2023 Q4 | 7.18 Million USD | -56.59% |
| 2023 Q1 | 23.85 Million USD | -31.09% |
| 2023 FY | 7.18 Million USD | -79.24% |
| 2023 Q2 | 23.96 Million USD | 0.44% |
| 2023 Q3 | 16.55 Million USD | -30.92% |
| 2022 Q1 | 32.26 Million USD | 72.97% |
| 2022 FY | 34.62 Million USD | 85.61% |
| 2022 Q4 | 34.62 Million USD | 37.1% |
| 2022 Q3 | 25.25 Million USD | -12.58% |
| 2022 Q2 | 28.88 Million USD | -10.46% |
| 2021 Q1 | 31.12 Million USD | -24.41% |
| 2021 Q4 | 18.65 Million USD | -44.98% |
| 2021 Q2 | 43.43 Million USD | 39.55% |
| 2021 FY | 18.65 Million USD | -54.69% |
| 2021 Q3 | 33.9 Million USD | -21.93% |
| 2020 FY | 41.16 Million USD | 210.0% |
| 2020 Q2 | -2.82 Million USD | -122.0% |
| 2020 Q1 | 12.83 Million USD | 134.24% |
| 2020 Q3 | 11.36 Million USD | 502.69% |
| 2020 Q4 | 41.16 Million USD | 262.28% |
| 2019 FY | -37.42 Million USD | -145.03% |
| 2019 Q4 | -37.47 Million USD | -1.92% |
| 2019 Q3 | -36.76 Million USD | -59.13% |
| 2019 Q2 | -23.1 Million USD | 32.48% |
| 2019 Q1 | -34.22 Million USD | -122.89% |
| 2018 Q1 | -62.75 Million USD | -759.88% |
| 2018 FY | -15.27 Million USD | -115.26% |
| 2018 Q4 | -15.35 Million USD | 46.87% |
| 2018 Q3 | -28.89 Million USD | 15.42% |
| 2018 Q2 | -34.16 Million USD | 45.56% |
| 2017 FY | -7.09 Million USD | 92.05% |
| 2017 Q4 | -7.29 Million USD | 0.0% |
| 2017 Q1 | 89.28 Million USD | 0.0% |
| 2016 FY | -89.28 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 106.981% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 123.023% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 96.371% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 77.46% |
| bluebird bio, Inc. | 108.57 Million USD | 93.38% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 179.714% |
| Imunon, Inc. | -4.69 Million USD | 252.939% |
| Editas Medicine, Inc. | -87.11 Million USD | 108.25% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.944% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 99.657% |
| Myriad Genetics, Inc. | 88.1 Million USD | 91.842% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 95.946% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 121.436% |
| Verastem, Inc. | -37.27 Million USD | 119.279% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.913% |
| Waters Corporation | 1.96 Billion USD | 99.633% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.973% |
| Biogen Inc. | 6.28 Billion USD | 99.886% |
| Nektar Therapeutics | 210.24 Million USD | 96.582% |
| Perrigo Company plc | 3.32 Billion USD | 99.784% |
| Dynavax Technologies Corporation | 106.63 Million USD | 93.26% |
| Illumina, Inc. | 1.21 Billion USD | 99.408% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -3.142% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 106.311% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 95.046% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 98.102% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 201.225% |
| Evolus, Inc. | 63.7 Million USD | 88.719% |
| Adicet Bio, Inc. | -142 Million USD | 105.061% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 119.528% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 126.52% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 98.433% |
| FibroGen, Inc. | 56.76 Million USD | 87.339% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 99.372% |
| OPKO Health, Inc. | 230.68 Million USD | 96.884% |
| Homology Medicines, Inc. | 18.43 Million USD | 61.019% |
| Geron Corporation | 14.76 Million USD | 51.311% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 99.547% |
| Exelixis, Inc. | -73.05 Million USD | 109.838% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 113.246% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 104.759% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 106.451% |
| Zoetis Inc. | 4.76 Billion USD | 99.849% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 103.597% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 171.363% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.075% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 149.321% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 99.318% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 99.258% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 105.308% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 99.48% |
| Blueprint Medicines Corporation | 702.83 Million USD | 98.977% |
| Insmed Incorporated | 721.62 Million USD | 99.004% |
| TG Therapeutics, Inc. | 17.86 Million USD | 59.764% |
| Incyte Corporation | -3.17 Billion USD | 100.226% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 99.062% |